Alzheimer’s diagnostics market seen reaching $11.89 billion by 2030

The Alzheimer’s disease diagnostics market is projected to keep expanding as older populations, chronic disease rates and demand for earlier detection push hospitals and diagnostic centers toward imaging, biomarker and genetic testing tools. The Business Research Company forecasts the market will rise from $8.03 billion in 2026 to $11.89 billion by 2030.

Why it matters: - Alzheimer’s diagnostics are becoming more important as health systems look for earlier detection tools that can guide care before the disease advances. - Demand is rising because Alzheimer’s cases are increasing and chronic conditions such as cardiovascular disease, diabetes and hypertension are linked to higher dementia risk. - The market’s growth points to wider adoption of biomarker testing, imaging and cognitive assessment tools across clinical settings.

What happened: - The Business Research Company released its Alzheimer’s Disease Diagnostic Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market grew from $7.26 billion in 2025 to $8.03 billion in 2026. - The report forecasts the market will reach $11.89 billion by 2030, implying a 10.3% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Alzheimer’s diagnostics include cognitive function tests, MRI scans, PET scans and biomarker assays using cerebrospinal fluid or blood samples. - Biomarker tests look for amyloid-beta and tau proteins. - The historical market expansion was supported by more Alzheimer’s cases, higher awareness of neurodegenerative disease, broader use of MRI and PET imaging, more diagnostic centers and hospitals, and more investment in cognitive assessment research. - Future growth is expected to come from novel biomarkers, new imaging tracers, AI-supported earlier diagnosis, more government and private funding, personalized medicine advances and multi-center clinical trials. - Key trends in the market include biomarker-based diagnostics, neuroimaging for early detection, expanded cognitive testing, genetic testing for risk assessment and multi-modal diagnostic approaches. - Heritage Health Services reported in November 2023 that 6.7 million Americans age 65 and older were living with Alzheimer’s dementia. - Heritage Health Services also reported prevalence rates of 5.0% for ages 65–74, 13.1% for ages 75–84 and 33.3% for people 85 and older. - Heritage Health Services projected nearly 13 million Americans could be affected by 2050.

Between the lines: - The market’s momentum reflects a shift from late-stage dementia management toward earlier detection and risk assessment. - The strong growth forecast suggests diagnostics are moving from a narrow specialist use case into a broader, more integrated part of neurological care. - The report’s regional split suggests mature markets are still dominant, while emerging healthcare investment is creating faster growth in Asia-Pacific.

What’s next: - The report expects adoption to accelerate as healthcare systems incorporate more biomarker, imaging and AI-enabled diagnostic methods. - Multi-modal diagnostic workflows are likely to become more common as clinicians combine cognitive, imaging and blood-based evidence. - The Business Research Company said the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - Download a free sample of the report - View the full market report - The report also says it covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Alzheimer’s diagnostics are moving deeper into a growth cycle driven by earlier detection, aging populations and more advanced testing tools.